通化東寶(600867.SH):擬1億元認購君合盟新增的950.31萬元註冊資本
格隆匯5月7日丨通化東寶(600867.SH)公佈,公司與君合盟及東寶集團、上海梓罡、上海崧原等君合盟股東方簽署《君合盟生物製藥(杭州)有限公司之增資協議》。公司作為B輪投資者,以人民幣10,000萬元認購君合盟新增的人民幣950.31萬元註冊資本,剩餘部分計入資本公積,以取得本次增資完成後在全面稀釋基礎上君合盟8.6759%股權。
君合盟是一家前沿蛋白藥物的創新企業,在神經治療、皮膚抗衰、皮下填充、內分泌等領域,從事重組蛋白質創新藥物的開發以及合成生物學領域創新產品開發,主要在研產品有JHM03(重組A型肉毒毒素)、JHM08(重組I型人膠原蛋白)、JHM09(重組III型人膠原蛋白)、JHM01(重組人生長激素注射液)和JHM02(重組長效生長激素注射液)。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.